Sanofi's focus on development prompts share price drop
The message to invest more broadly in research and development of its pipeline comes in the wake of Sanofi’s Q3 results.
by marketwire
French pharmaceutical giant Sanofi takes a heavy blow on the Paris stock exchange on Friday, after the company announced in connection with its financial statements that it will prioritize investment in research and development of medicines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Sanofi ready with phase II data for new eczema drug
For subscribers
Sanofi follows Lilly, Novo in cutting insulin prices
For subscribers
